Research has shown that ?9-THC, the main active ingredient in medical marijuana, decreases ß-amyloid plaques and neurodegeneration in Alzheimer’s disease, and that it is reduced further by the addition of a COX-2 inhibitor. A COX-2 inhibitor is a form of NSAID that is used to reduce pain.
The combination of a COX-2 inhibitor with medical cannabis also prevents marijuana-induced memory problems and ‘brain fog’ or ‘haze’ that is common.
Furthermore, COX inhibitors have been shown to reduce the occurrence of cancers and pre-cancerous growths.
SK3 Group president Artemus Mayor noted the company sees this as an opportunity to help the many people suffering with Alzheimer’s disease.
"Our new Alzatrex™ product will not only help those with Alzheimer’s and dementia, but it will also help medical marijuana patients reduce the side-effects of cannabis, mainly the ‘brain fog’ that is so common. We are using technology to improve the lives of patients," Mayor added.
Alzatrex will be available soon in dispensaries and delivery services across California, to start.